Allergan Inc posted its third-quarter earnings in 2008, with neuromodulator drug Botox as its top seller. Below is the list of the company´s top selling drugs in the first nine months of the year.

King Pharmaceuticals Inc posted a better-than-expected quarterly profit, helped by sales of its injectable products.

King Pharmaceuticals posted its third-quarter earnings for this year, showing skeletal muscle relaxant Skelaxin as its top seller. Below is the list of the company´s best selling drugs in the first nine months of 2008.

Israel-based generics specialist Teva Pharmaceuticals Industries Ltd posted its third-quarter 2008 earnings, with multiple scelerosis treatment Copaxone as top seller – almost reaching blockbuster status in the U.S. Below is a list of the company´s widest sold drugs in the first nine months of the year.

Teva Pharmaceutical Industries Ltd, the world´s biggest maker of generic drugs, beat forecasts for third-quarter net profit due to strong drug sales.

Sanofi-Aventis SA, the world´s third largest drugmaker, raised 2008 growth forecasts but reported little changed third quarter net profit, after generics of several top drugs came onto the market.

Sanofi-Aventis SA posted its third-quarter 2008 results, with blockbuster anti-thrombosis drug Lovenox and blood thinner Plavix still in top places. Below is the list of the Paris-based company´s best selling drugs for the first nine months of the year.

Denmark’s Novo Norkisk A/S reported its third-quarterly earnings for 2008, with Novoseven factor VIIa in top place. Below is the list of the company’s widest selling drugs in the first nine months of the year.

U.K.-based AstraZeneca Plc’s third-quarter report revealed it had the best performance up the present of European pharmaceutical companies, gaining a 28 percent profit compared to last year’s same period by trimming costs and expanding sales outside the U.S.

Anglo-Swedish pharma AstraZeneca posted this year’s third-quarter earnings, with ulcer treatment Nexium, anti-psychotic Seroquel and statin Crestor leading sales. Below is a list of the company’s top sellers in the first nine months of the year.

U.K.-based Shire Plc’s third quarter earnings posting equaled the market’s estimates, its hyperactivity drugs selling well, while there was a rise in its Hunter´s syndrome medication Elaprase.

U.K.-based Shire Plc posted its third-quarter earnings, revealing attention-deficit and hyperactivity disorder (ADHD) Adderall XR as its top earner. Below is the listing of the company’s top selling drugs in the first nine months of the year.

Defying a drop in its plastics and foams unit and noting strong demand for its prescription drugs and its farming pesticides, Germany´s Bayer AG remained firm regarding its full-year guidance forecast. Further details.

Germany´s Bayer AG posted its third-quarter earnings, revealing its Yaz, Yasmin and Yasminelle group of birth control pills have now reached the blockbuster stage. Below is a list of the company´s best selling drugs in the first nine months of the year.

Merck KGaA posted its third quarter earnings for 2008, with multiple sclerosis drug Rebif taking top place. Below is the list of the company´s drug sales in the first nine months of the year.

German pharmaceutical-and-chemicals company Merck KGaA reported a sharp rise in third-quarter net profits (€200.1 million) compared to a year earlier (€36.2 million), but lowered its expected 2008 earnings guidance.

Wyeth posted this year´s third quarter earnings, with anti-depressant Effexor topping the list, followed by pneumococcal vaccine Prevnar. Below sales of the company´s best selling drugs in the first nine months of the year.

Wyeth reported results for the 2008 third quarter and first nine months of this year, revealing a net revenue increase of 4 percent in the third quarter compared to the same period last year, and a 5 percent increase for nine months overall.

Bristol-Myers Squibb reported on its third-quarter earnings in 2008, with anti-clotting drug Plavix still taking top place. Below is the listing of the company´s sales of drugs in the first nine months of the year.

Bristol-Myers Squibb appears another loser in its third-quarter earnings, reporting third-quarter profit fell 22 percent on a $ 224 million loss from investments in subprime securities. However, revenue rose 14 percent to $ 5.25 billion dollars.